BTK and B-cell chronic lymphocytic leukemia: While ibrutinib may act through BTK-dependent and -independent mechanisms [25], it is likely that the anti-CLL effect observed with the co-administration of ibrutinib and idelalisib is mediated via the direct inhibition of both pathways in tumor cells and potentially through the modulation of the immune response.